Skip to main content
SpringerLink
Log in

Osteoprotegerin, Receptor Activator of Nuclear Factor Kappa B Ligand, and Growth Hormone/Insulin-Like Growth Factor-1 Axis in Children with Growth Hormone Deficiency

  • Chapter
  • First Online:
Clinical Medicine Research

Part of the book series: Advances in Experimental Medicine and Biology ((CLEXBI,volume 1116 ))

Abstract

The growth hormone/insulin-like growth factor-1 (GH/IGF-1) axis is involved in the regulation of the receptor activator of nuclear factor kappa B ligand (RANKL)/RANK/osteoprotegerin (OPG) system, but the exact mechanism of the associations is not fully explained. In this study we investigated the serum OPG and total sRANKL concentrations in short children who had differences in GH secretory status. We also investigated the associations between the GH/IGF-1 and OPG/RANKL systems in GH-deficient children during GH treatment. There were no significant differences in any anthropometric or biochemical parameters evaluated between the GH-deficient and GH-sufficient children. The OPG content and total alkaline phosphatase (ALP) activity increased significantly after the initiation of GH treatment, while total sRANKL remained unchanged. The variables baseline BMI SDS for height-age (β = 0.42; p < 0.05), baseline ALP activity (β = 0.36; p < 0.05), weight SDS for height-age at 6 months of GH treatment (β = 1.86; p < 0.01), and total ALP activity at 6 months of GH treatment (β = 0.48, p < 0.01) were identified as independent predictors of ΔOPG6-month-baseline. We conclude that OPG and total sRANKL concentrations are independent from GH secretory status in short children. OPG elevation during GH treatment is independently associated with total ALP activity and nutritional status in GH-deficient children.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Abrahamsen B, Hjelmborg JV, Kostenuik P, Stilgren LS, Kyvik K, Adamu S, Brixen K, Langdahl BL (2005) Circulating amounts of osteoprotegerin and RANKL ligand: genetic influence and relationship with BMD assessed in female twins. Bone 36(4):727–735

    Article  CAS  Google Scholar 

  • Andersson B, Swolin–Eide D, Magnusson P, Albertsson–Wikland K (2015) Short–term changes in bone formation markers following growth hormone (GH) treatment in short prepubertal children with a broad range of GH secretion. Clin Endocrinol 82(1):91–99

    Article  CAS  Google Scholar 

  • Boyce BF, Xing L (2008) Functions of RANKL/RANK/OPG in bone modelling and remodelling. Arch Biochem Biophys 473(2):139–146

    Article  CAS  Google Scholar 

  • Burguera B, Hofbauer LC, Thomas T, Gori F, Evans GL, Khosla S, Riggs BL, Turner RT (2001) Leptin reduces ovariectomy induced bone loss in rats. Endocrinology 142:3546–3553

    Article  CAS  Google Scholar 

  • Buzi F, Maccarinelli G, Guaragni B, Ruggeri F, Radetti G, Meini A, Mazzolari E, Cocchi D (2004) Serum osteoprotegerin and receptor activator of nuclear factor κB (RANKL) concentrations in normal children and in children with pubertal precocity, Turner’s syndrome, and rheumatoid arthritis. Clin Endocrinol 60:87–91

    Article  CAS  Google Scholar 

  • Erol M, Bostan Gayret O, Tekin Nacaroglu H, Yigit O, Zengi O, Salih Akkurt M, Tasdemir M (2016) Association of osteoprotegerin with obesity, insulin resistance and non–alcoholic fatty liver disease in children. Iran Red Crescent Med J 18(11):e41873. https://doi.org/10.5812/ircmj.41873

    Article  PubMed  PubMed Central  Google Scholar 

  • Flint J, Wu S, Shott S, Suarez E, De Luca F (2009) Relationships between Osteoprotegerin (OPG), receptor activator of nuclear factor kappa B ligand (RANKL), and growth hormone (GH) secretory status in short children. J Pediatr Endocrinol Metab 22(12):1105–1112

    Article  CAS  Google Scholar 

  • Friedmann A, Ozmeric N, Bernimoulin JP, Kleber BM, Ayhan E, Aykan T, Gökmenoǧlu C (2014) Receptor activator of NF–kappa B ligand (RANKL) and CD 31 expressions in chronic periodontitis patients before and after surgery. Cent Eur J Immunol 39(4):508–517

    Article  CAS  Google Scholar 

  • Giustina A, Mazziotti G, Canalis E (2008) Growth hormone, insulin–like growth factors, and the skeleton. Endocr Rev 29(5):535–559

    Article  CAS  Google Scholar 

  • Greulich WW, Pyle SI (1969) Radiographic atlas of skeletal development of the hand and wrist. Stanford University Press, Stanford

    Google Scholar 

  • Guerra–Menéndez L, Sádaba MC, Puche JE, Lavandera JL, de Castro LF, de Gortázar AR, Castilla–Cortázar I (2013) IGF–1 increases markers of osteoblastic activity and reduces bone resorption via osteoprotegerin and RANKL–ligand. J Transl Med 11:271

    Article  Google Scholar 

  • Hofbauer LC, Schoppet M (2004) Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 292:490–495

    Article  CAS  Google Scholar 

  • Ikeda T, Kasai M, Utsuyama M, Hirokawa K (2001) Determination of three isoforms of the receptor activator of nuclear factor–[kappa]B ligand and their differential expression in bone and thymus. Endocrinology 142:1419–1426

    Article  CAS  Google Scholar 

  • Kearns AE, Khosla S, Kostenuik P (2008) Receptor activator of nuclear factor kappa B ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev 29(2):155–192

    Article  CAS  Google Scholar 

  • Khosla S (2001) Minireview: the OPG/RANKL/RANK system. Endocrinology 142:5050–5055

    Article  CAS  Google Scholar 

  • Kohli SS, Kohli VS (2011) Role of RANKL–RANK/Osteoprotegerin molecular complex in bone remodelling and its immunopathologic implications. Indian J Endocrinol Metab 15(3):175–181

    Article  CAS  Google Scholar 

  • Kruk B, Kraj M, Centkowski P, Sokołowska U (2002) Osteoprotegerin and sRANKL serum levels in multiple myeloma patients. Cent Eur J Immunol 27(4):129–135

    Google Scholar 

  • Kudlacek S, Schneider B, Woloszczuk W, Pietschmann P, Willvonseder R, Austrian Study Group on Normative Values of Bone Metabolism (2003) Serum levels of osteoprotegerin increase with age in a healthy adult population. Bone 32(6):681–686

    Article  CAS  Google Scholar 

  • Lanzi R, Losa M, Villa I, Gatti E, Sirtori M, Dal Fiume C, Rubinacci A (2003) GH replacement therapy increases plasma osteoprotegerin levels in GH–deficient adults. Eur J Endocrinol 148:185–191

    Article  CAS  Google Scholar 

  • Lee S, Lorenzo J (1999) Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast–like cell formation. Endocrinology 140(8):3552–3561

    Article  CAS  Google Scholar 

  • Li Y, Toraldo G, Li A, Yang X, Zhang H, Qian WP, Weitzmann MN (2007) B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo. Blood 109:3839–3848

    Article  CAS  Google Scholar 

  • Ma YL, Cain RL, Halladay DL, Yang X, Zeng Q, Miles RR, Chandrasekhar S, Martin TJ, Onyia JE (2001) Catabolic effects of continuous human PTH in vivo is associated with sustained stimulation of RANKL and inhibition of OPG and gene–associated bone formation. Endocrinology 142:4047–4054

    Article  CAS  Google Scholar 

  • Meazza C, Elsedfy HH, Pagani S, Bozzola E, El Kholy M, Bozzola M (2014) Metabolic parameters and adipokine profile in growth hormone deficient (GHD) children before and after 12–month GH treatment. Horm Metab Res 46:219–223

    CAS  PubMed  Google Scholar 

  • Mrak E, Villa I, Lanzi R, Losa M, Guidobono F, Rubinacci A (2007) Growth hormone stimulates osteoprotegerin expression and secretion in human osteoblast–like cells. J Endocrinol 192:639–645

    Article  CAS  Google Scholar 

  • Mundy GR, Oyajobi B, Traianedes K, Dallas S, Chen D (2001) Cytokines and bone remodelling. In: Marcus R, Feldman D, Kelsey J (eds) Osteoporosis. Academic, San Diego

    Google Scholar 

  • Nielsen HK, Jorgensen JO, Brixen K, Christiansen JS (1991) Serum osteocalcin and bone isoenzyme alkaline phosphatase in growth hormone deficient patients: dose–response studies with biosynthetic human GH. Calcif Tissue Int 48:82–87

    Article  CAS  Google Scholar 

  • Rubin J, Ackert–Bicknell CL, Zhu L, Fan X, Murphy TC, Nanes MS, Marcus R, Holloway L, Beamer WG, Rosen CJ (2002) IGF–I regulates osteoprotegerin (OPG), and receptor activator of nuclear factor–Κb ligand in vitro and OPG in vivo. J Clin Endocrinol Metab 87(9):4273–4279

    Article  CAS  Google Scholar 

  • Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Lüthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw–Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89(2):309–319

    Article  CAS  Google Scholar 

  • Siomou E, Challa A, Printza N, Giapros V, Petropopulou F, Mitsioni A, Papachristou F, Stefanidis CJ (2011) Serum osteoprotegerin, RANKL and fibroblast growth factor–23 in children with chronic kidney disease. Pediatr Nephrol 26:1105–1114

    Article  Google Scholar 

  • Szulc P, Hofbauer LC, Delmas PD (2001) OPG serum levels in men: correlation with age, estrogen and testosterone status. J Clin Endocrinol Metab 86:3162–3165

    CAS  PubMed  Google Scholar 

  • Takayanagi H (2007) Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol 7:292–304

    Article  CAS  Google Scholar 

  • Tanner JM (1962) Growth at adolescence. Blackwell, Oxford

    Google Scholar 

  • Theoleyre S, Wittrant Y, Tat SK, Fortun Y, Redini F, Heymann D (2004) The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodelling. Cytokine Growth Factor Rev 15:457–475

    Article  CAS  Google Scholar 

  • Ueland T, Bollerslev J (2005) Bone metabolism and growth hormone deficiency. In: Jorgensen JOL, Christiansen JS (eds) Frontiers in hormone research. Karger, Basel

    Google Scholar 

  • Ueland T, Bollerslev J, Godang K, Muller FS, Aukrust P (2001) Increased serum osteoprotegerin in disorders characterized by persistence autoimmune activation or glucocorticoid excess – possible role in bone homeostasis. Eur J Endocrinol 145:685–690

    Article  CAS  Google Scholar 

  • Ueland T, Bollerslev J, Flyvbjerg A, Hansen TB, Vahl N, Mosekilde L (2002) Effects of 12 months of GH treatment on cortical and trabecular bone content of IGFs and OPG in Adults with acquired GH deficiency: a double–blind, randomized, placebo–controlled study. J Clin Endocrinol Metab 87:2760–2763

    Article  CAS  Google Scholar 

  • Ueland T, Odgren PR, Yndestad A, Godang K, Schreiner T, Marks SC Jr, Bollerslev J (2003) Growth hormone substitution increases gene expression of members of the IGF–1 family in cortical bone from women with adult onset growth hormone deficiency–relationship with bone turn–over. Bone 33:638–645

    Article  CAS  Google Scholar 

  • Vega D, Maalouf NM, Sakhaee K (2007) The role of receptor activator of nuclear factor–κB (RANK)/RANK Ligand/Osteoprotegerin: clinical implications. J Clin Endocrinol Metab 92:4514–4521

    Article  CAS  Google Scholar 

  • Wada T, Nakashima T, Hiroshi N, Penninger JM (2006) RANKL–RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med 12:17–25

    Article  CAS  Google Scholar 

  • Wang Y, Nishida S, Elalieh HZ, Long RK, Halloran BP, Bikle D (2006) Role of IGF–1 signaling in regulating osteoclastogenesis. J Bone Miner Res 21:1350–1358

    Article  CAS  Google Scholar 

  • Wasilewska A, Rybi–Szuminska AA, Zoch–Zwierz W (2009) Serum ostoprotegerin (OPG) and receptor activator of nuclear factor kappa B (RANKL) in healthy children and adolescents. J Pediatr Endocrinol Metab 22(12):1099–1104

    Article  CAS  Google Scholar 

  • Witkowska–Sędek E, Kucharska A, Rumińska M, Pyrżak B (2016) Relationship between 25(OH)D and IGF–I in children and adolescents with growth hormone deficiency. Adv Exp Med Biol 912:43–49

    Article  Google Scholar 

  • Witkowska–Sędek E, Stelmaszczyk–Emmel A, Kucharska A, Demkow U, Pyrżak B (2017) Association between vitamin D and carboxy–terminal cross–linked telopeptide of type I collagen in children during growth hormone replacement therapy. Adv Exp Med Biol 1047:53–60

    Article  Google Scholar 

  • Witkowska–Sędek E, Stelmaszczyk–Emmel A, Majcher A, Demkow U, Pyrżak B (2018) The relationship between alkaline phosphatase and bone alkaline phosphatase activity and the growth hormone/insulin–like growth factor–1 axis and vitamin D status in children with growth hormone deficiency. Acta Biochim Pol 65(2):269–275

    PubMed  Google Scholar 

  • Xia J, Ren W, Zheng X, Liu C, Li J, Chen T, Li X, Wang L, Hu Y (2015) Correlation of increased plasma osteoprotegerin and cardiovascular risk factors in patients with adult growth hormone deficiency. Int J Clin Exp Med 8(3):3184–3192

    CAS  PubMed  PubMed Central  Google Scholar 

  • Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T (1998) Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis–inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A 95(7):3597–3602

    Article  CAS  Google Scholar 

  • Yates L, Górecki DC (2006) The nuclear factor–kappa B (NF–κB): from a versatile transcription factor to a ubiquitous therapeutic target. Acta Biochim Pol 53(4):651–662

    CAS  PubMed  Google Scholar 

Download references

Conflicts of Interest

The authors declare no conflicts of interest in relation to this article.

Ethical Approval

All procedures performed in this study were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and its later amendments. The study protocol was approved by the Bioethics Committee of the Medical University of Warsaw (permit: KB/93/2016).

Informed Consent

Informed written consent was obtained from all individual participants included in the study or from their parents and legal guardians.

Author information

Authors and Affiliations

  1. Department of Paediatrics and Endocrinology, Medical University of Warsaw, Warsaw, Poland

    Ewelina Witkowska-Sędek, Małgorzata Rumińska & Beata Pyrżak

  2. Department of Laboratory Diagnostics and Clinical Immunology of Developmental Age, Medical University of Warsaw, Warsaw, Poland

    Anna Stelmaszczyk-Emmel & Urszula Demkow

  3. Department of Biophysics and Human Physiology, Medical University of Warsaw, Warsaw, Poland

    Maria Sobol

Authors
  1. Ewelina Witkowska-Sędek
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Małgorzata Rumińska
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anna Stelmaszczyk-Emmel
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Maria Sobol
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Urszula Demkow
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Beata Pyrżak
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ewelina Witkowska-Sędek .

Editor information

Editors and Affiliations

  1. Opole Medical School, Opole, Poland

    Mieczyslaw Pokorski

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Witkowska-Sędek, E., Rumińska, M., Stelmaszczyk-Emmel, A., Sobol, M., Demkow, U., Pyrżak, B. (2018). Osteoprotegerin, Receptor Activator of Nuclear Factor Kappa B Ligand, and Growth Hormone/Insulin-Like Growth Factor-1 Axis in Children with Growth Hormone Deficiency. In: Pokorski, M. (eds) Clinical Medicine Research. Advances in Experimental Medicine and Biology(), vol 1116 . Springer, Cham. https://doi.org/10.1007/5584_2018_274

Download citation

Publish with us

Policies and ethics

Search

Navigation